Skip to main content

Table 2 Dose modification of Irinotecan and 5-fluorouracil (5-FU) (N = 89)

From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

  Dose Level Dose (mg/m2) N % Duration until modification (days)
  Median Range
Irinotecan 0 180 52 58.4 - -
  −1 150 37 41.6 33.0 (14–448)
  −2 125 12 13.5 76.5 (14–146)
  −3 100 3 3.4 112.0 (47–181)
5-FU (bolus/infusion)* 0 400/2,400 55 61.8 - -
  −1 400/2,000 34 38.2 47.5 (14–448)
  −2 0/1,600 9 10.1 82.0 (33–301)
  1. *No patient had the dose of only bolus or infusion of 5-FU reduced.